BRIAN GILBERT to Respiratory Syncytial Viruses
This is a "connection" page, showing publications BRIAN GILBERT has written about Respiratory Syncytial Viruses.
Connection Strength
0.436
-
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016 01; 60(1):6-13.
Score: 0.107
-
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015 Feb 26; 58(4):1630-43.
Score: 0.102
-
Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22; 111(16):5992-7.
Score: 0.097
-
Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res. 2005 Oct; 68(1):18-26.
Score: 0.054
-
Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Res. 2003 Nov; 60(3):221-31.
Score: 0.047
-
A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. J Virol. 2016 08 15; 90(16):7508-7518.
Score: 0.028